Invention Grant
US08183207B2 Treatment of osteolytic disorders and cancer using CSF1R extracellular domain fusion molecules
有权
使用CSF1R细胞外结构域融合分子治疗溶骨性疾病和癌症
- Patent Title: Treatment of osteolytic disorders and cancer using CSF1R extracellular domain fusion molecules
- Patent Title (中): 使用CSF1R细胞外结构域融合分子治疗溶骨性疾病和癌症
-
Application No.: US12626583Application Date: 2009-11-25
-
Publication No.: US08183207B2Publication Date: 2012-05-22
- Inventor: Haishan Lin , Li Long
- Applicant: Haishan Lin , Li Long
- Applicant Address: US CA South San Francisco
- Assignee: Five Prime Therapeutics, Inc.
- Current Assignee: Five Prime Therapeutics, Inc.
- Current Assignee Address: US CA South San Francisco
- Agency: Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P.
- Main IPC: A61P19/08
- IPC: A61P19/08 ; A61K38/16 ; A61K38/18 ; C07K14/53 ; C12N15/00
Abstract:
Methods of using colony stimulating factor receptor (CSF1R) extracellular domain (ECD) fusion molecules for treating osteolytic bone loss, cancer metastasis, cancer metastasis-induced osteolytic bone loss, and tumor growth are provided. CSF1R ECD fusion molecules, polynucleotides encoding CSF1R ECD fusion molecules, and methods of making CSF1R ECD fusion molecules are also provided.
Public/Granted literature
- US20100136006A1 TREATMENT OF OSTEOLYTIC DISORDERS AND CANCER USING CSF1R EXTRACELLULAR DOMAIN FUSION MOLECULES Public/Granted day:2010-06-03
Information query
